Thermo Fisher Scientific (TMO) 10-Q 3 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 30, 2019shares
Document and Entity Information [Abstract]
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Central Index Key	0000097745
Document Type	10-Q
Document Period End Date	Mar. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	399,981,140
Entity Stock Trading Symbol	TMO

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Mar. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 1,106	$ 2,103
Accounts receivable, less allowances of $114 and $117	4,155	4,136
Inventories	3,124	3,005
Other current assets	1,554	1,381
Total current assets	9,939	10,625
Property, Plant and Equipment, Net	4,192	4,165
Acquisition-related Intangible Assets, Net	14,489	14,978
Other Assets	1,740	1,117
Goodwill	25,236	25,347
Total Assets	55,596	56,232
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	1,336	1,271
Accounts payable	1,462	1,615
Accrued payroll and employee benefits	704	982
Contract liabilities	967	809
Other accrued expenses	1,429	1,470
Total current liabilities	5,898	6,147
Deferred Income Taxes	2,145	2,265
Other Long-term Liabilities	3,048	2,515
Long-term Obligations	16,812	17,719
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 432,856,849 and 431,566,561 shares issued	433	432
Capital in excess of par value	14,771	14,621
Retained earnings	19,439	18,696
Treasury stock at cost, 32,875,709 and 29,444,882 shares	(4,441)	(3,665)
Accumulated other comprehensive items	(2,509)	(2,498)
Total shareholders' equity	27,693	27,586
Total Liabilities and Shareholders' Equity	$ 55,596	$ 56,232

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Mar. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 114	$ 117
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	432,856,849	431,566,561
Treasury Stock at Cost (in shares)	32,875,709	29,444,882

Consolidated Statement of Incom

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Revenues
Revenues	$ 6,125	$ 5,853
Costs and Operating Expenses:
Selling, general and administrative expenses	1,528	1,515
Research and development expenses	248	234
Restructuring and other costs, net	11	45
Total costs and operating expenses	5,205	5,067
Operating Income	920	786
Other Expense, Net	(103)	(152)
Income Before Income Taxes	817	634
Provision for Income Taxes	(2)	(55)
Net Income	$ 815	$ 579
Earnings per Share
Basic (in dollars per share)	$ 2.04	$ 1.44
Diluted (in dollars per share)	$ 2.02	$ 1.43
Weighted Average Shares
Basic (in shares)	400	402
Diluted (in shares)	403	406
Product [Member]
Revenues
Revenues	$ 4,720	$ 4,528
Costs and Operating Expenses:
Cost of revenues	2,414	2,325
Service [Member]
Revenues
Revenues	1,405	1,325
Costs and Operating Expenses:
Cost of revenues	$ 1,004	$ 948

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Comprehensive Income
Net Income	$ 815	$ 579
Other Comprehensive Items:
Currency translation adjustment (net of tax provision (benefit) of $45 and ($47))	(15)	47
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $1 and $1)	2	2
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $0 and ($1))	1	(2)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $1 and $1)	1	2
Total other comprehensive items	(11)	49
Comprehensive Income	$ 804	$ 628

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 45	$ (47)
Tax provision (benefit) on reclassification adjustment for losses on hedging instruments recognized in net income	(1)	(1)
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	0	(1)
Tax provision (benefit) on amortization of net loss and prior service benefit included in net periodic pension cost	$ (1)	$ (1)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Operating Activities
Net Income	$ 815	$ 579
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	133	131
Amortization of acquisition-related intangible assets	422	444
Change in deferred income taxes	(106)	(121)
Non-cash stock-based compensation	44	43
Other non-cash expenses, net	18	27
Changes in assets and liabilities, excluding the effects of acquisitions:
Accounts receivable	(29)	(71)
Inventories	(140)	(124)
Other assets	(117)	(241)
Accounts payable	(129)	(94)
Other liabilities	(230)	(471)
Contributions to retirement plans	(32)	(24)
Net cash provided by operating activities	649	78
Investing Activities
Acquisitions, net of cash acquired	(1)	(57)
Purchase of property, plant and equipment	(201)	(118)
Proceeds from sale of property, plant and equipment	6	2
Other investing activities, net	15	(6)
Net cash used in investing activities	(181)	(179)
Financing Activities
Repayment of debt	(1)	(453)
Proceeds from issuance of commercial paper	100	1,306
Repayments of commercial paper	(787)	(1,124)
Purchases of company common stock	(750)	0
Dividends paid	(68)	(60)
Net proceeds from issuance of company common stock under employee stock plans	81	39
Other financing activities	0	(50)
Net cash (used in) provided by financing activities	(1,425)	(342)
Exchange Rate Effect on Cash	(32)	57
Increase in Cash, Cash Equivalents and Restricted Cash	(989)	(386)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	2,117	1,361
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 1,128	$ 975

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance (in shares) at Dec. 31, 2017		428			27
Balance at Dec. 31, 2017	$ 25,413	$ 428	$ 14,177	$ 15,914	$ (3,103)	$ (2,003)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes	30			118		(88)
Issuance of shares under employees' and directors' stock plans (in shares)		1			0
Issuance of shares under employees' and directors' stock plans	51	$ 1	72		$ (22)
Stock-based compensation	43		43
Dividends declared	(69)			(69)
Net Income	579			579
Other comprehensive items	49					49
Other	27		27
Balance (in shares) at Mar. 31, 2018		429			27
Balance at Mar. 31, 2018	26,123	$ 429	14,319	16,542	$ (3,125)	(2,042)
Balance (in shares) at Dec. 31, 2018		432			29
Balance at Dec. 31, 2018	27,586	$ 432	14,621	18,696	$ (3,665)	(2,498)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes	4			4		0
Issuance of shares under employees' and directors' stock plans (in shares)		1			1
Issuance of shares under employees' and directors' stock plans	81	$ 1	106		$ (26)
Stock-based compensation	44		44
Purchases of company common stock (in shares)					3
Purchases of company common stock	(750)				$ (750)
Dividends declared	(76)			(76)
Net Income	815			815
Other comprehensive items	(11)					(11)
Balance (in shares) at Mar. 30, 2019		433			33
Balance at Mar. 30, 2019	$ 27,693	$ 433	$ 14,771	$ 19,439	$ (4,441)	$ (2,509)

Consolidated Statement of Sha_2

Consolidated Statement of Shareholders' Equity Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.19	$ 0.17

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1 . Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at March 30, 2019 , the results of operations for the three-month periods ended March 30, 2019 and March 31, 2018 , and the cash flows for the three-month periods ended March 30, 2019 and March 31, 2018 . Interim results are not necessarily indicative of results for a full year. The consolidated balance sheet presented as of December 31, 2018 , has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2018 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Note 1 to the consolidated financial statements for 2018 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. Except for the accounting for leases, as noted below, there have been no material changes in the company’s significant accounting policies during the three months ended March 30, 2019 . Leases The company determines whether an arrangement is, or contains, a lease at inception. Prior to 2019, the company generally accounted for operating lease payments by charging them to expense as incurred. Beginning in 2019, operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Classification of operating lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes lease expense for these leases on a straight-line basis over the lease term. Because most of the company’s leases do not provide an implicit rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms may include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. As a lessee, the company accounts for the lease and non-lease components as a single lease component. See Note 9 additional information about the company's leases. Contract-related Balances Current contract assets and noncurrent contract assets are included within other current assets and other assets, respectively, in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: March 30, December 31, (In millions) 2019 2018 Current Contract Assets, Net $ 545 $ 459 Noncurrent Contract Assets, Net 15 15 Current Contract Liabilities 967 809 Noncurrent Contract Liabilities 497 355 In the first three months of 2019 , the company recognized revenue of $336 million that was included in the contract liabilities balance at December 31, 2018 . Contract liabilities increased during the first quarter of 2019 primarily due to an advance payment from a customer. Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Three Months Ended March 30, March 31, (In millions) 2019 2018 Beginning Balance $ 92 $ 87 Provision charged to income 27 31 Usage (28 ) (28 ) Adjustments to previously provided warranties, net (1 ) (1 ) Currency translation — 1 Ending Balance $ 90 $ 90 Inventories The components of inventories are as follows: March 30, December 31, (In millions) 2019 2018 Raw Materials $ 867 $ 812 Work in Process 472 430 Finished Goods 1,785 1,763 Inventories $ 3,124 $ 3,005 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2 ) and the ultimate loss from abandoning leases at facilities being exited (Note 14 ). Actual results could differ from those estimates. Recent Accounting Pronouncements In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company expects to adopt the guidance when it is effective in 2020 using a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company expects to adopt the guidance when it is effective in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018, the FASB issued additional guidance and clarification. The company expects to adopt the guidance when it is effective in 2020 using a modified retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. During 2017 - 2019, the FASB issued additional guidance and clarification. The guidance became effective for the company in 2019. The company has elected to adopt the guidance using a modified retrospective method, by applying the transition approach as of the beginning of the period of adoption. Comparative periods have not been restated. As permitted upon transition, the company did not reassess whether any expired or existing contracts were or contained embedded leases, the lease classification for any expired or existing leases, initial direct costs for any leases, or whether land easements met the definition of a lease if they were not accounted for as leases under the prior guidance. Adoption of the new guidance impacted the company’s Consolidated Balance Sheet as follows: (In millions) December 31, Impact of Adopting New Lease Guidance January 1, Other Assets $ 1,117 $ 641 $ 1,758 Other Accrued Expenses 1,470 132 1,602 Other Long-term Liabilities 2,515 505 3,020 Retained Earnings 18,696 4 18,700

Acquisitions and Dispositions

Acquisitions and Dispositions	3 Months Ended
	Mar. 30, 2019
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2 . Acquisitions and Dispositions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred. On April 30, 2019, the company acquired, within the Laboratory Products and Services segment, Brammer Bio for approximately $1.7 billion in cash. Brammer Bio is a leading viral vector contract development and manufacturing organization for gene and cell therapies. Revenues of Brammer Bio were approximately $140 million in 2018. The company expects to determine the preliminary purchase price allocation prior to the end of the second quarter of 2019. The company has entered into an agreement to acquire Gatan, Inc., a wholly owned subsidiary of Roper Technologies, Inc., for approximately $925 million in cash. Gatan is a leading manufacturer of instrumentation and software used to enhance and extend the operation and performance of electron microscopes. The transaction is subject to customary closing conditions, including regulatory approvals. Upon successful completion of the regulatory approval process, Gatan will become part of the Analytical Instruments segment. Disposition On January 28, 2019, the company entered into an agreement to sell its Anatomical Pathology business to PHC Holdings Corporation for approximately $1.14 billion . The business is part of the Specialty Diagnostics segment. Revenues in the first three months of 2019 and the full year 2018 of the business to be sold were approximately $85 million and $344 million , respectively. The sale is subject to customary closing conditions and is expected to close in the second quarter of 2019. The assets and liabilities of the Anatomical Pathology business were as follows on March 30, 2019: (In millions) March 30, 2019 Current Assets $ 85 Long-term Assets 540 Current Liabilities 32 Long-term Liabilities 33

Revenue

Revenue	3 Months Ended
	Mar. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3 . Revenue Disaggregated Revenue Revenue by type is as follows: Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues Consumables $ 3,230 3,111 Instruments 1,490 1,417 Services 1,405 1,325 Consolidated revenues $ 6,125 $ 5,853 Revenue by geographic region is as follows: Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues (a) North America $ 3,059 $ 2,903 Europe 1,519 1,518 Asia-Pacific 1,363 1,264 Other regions 184 168 Consolidated revenues $ 6,125 $ 5,853 (a) Revenues are attributed to regions based on customer location. Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenue by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 30, 2019 was $5.57 billion . The company will recognize revenue for these performance obligations as they are satisfied, approximately 85% of which is expected to occur within the next twelve months .

Business Segment and Geographic

Business Segment and Geographical Information	3 Months Ended
	Mar. 30, 2019
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 4 . Business Segment and Geographical Information The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation. Business Segment Information Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues Life Sciences Solutions $ 1,607 $ 1,499 Analytical Instruments 1,322 1,257 Specialty Diagnostics 957 947 Laboratory Products and Services 2,513 2,413 Eliminations (274 ) (263 ) Consolidated revenues 6,125 5,853 Segment Income (a) Life Sciences Solutions 561 517 Analytical Instruments 282 246 Specialty Diagnostics 242 243 Laboratory Products and Services 285 280 Subtotal reportable segments (a) 1,370 1,286 Cost of revenues charges, net (6 ) (3 ) Selling, general and administrative charges, net (11 ) (8 ) Restructuring and other costs, net (11 ) (45 ) Amortization of acquisition-related intangible assets (422 ) (444 ) Consolidated operating income 920 786 Other expense, net (b) (103 ) (152 ) Income from continuing operations before income taxes $ 817 $ 634 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments. Geographical Information Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues (c) United States $ 2,918 $ 2,756 China 654 541 Other 2,553 2,556 Consolidated revenues $ 6,125 $ 5,853 (c) Revenues are attributed to countries based on customer location.

Other Expense, Net

Other Expense, Net	3 Months Ended
	Mar. 30, 2019
Other Income and Expenses [Abstract]
Other Expense, Net [Text Block]	Note 5 . Other Expense, Net The components of other expense, net, in the accompanying statement of income are as follows: Three Months Ended March 30, March 31, (In millions) 2019 2018 Interest Income $ 67 $ 20 Interest Expense (189 ) (163 ) Other Items, Net 19 (9 ) Other Expense, Net $ (103 ) $ (152 ) Other Items, Net In all periods, other items, net includes currency transaction gains and losses on monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 6 . Income Taxes The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Three Months Ended March 30, March 31, (In millions) 2019 2018 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 172 $ 133 Increases (Decreases) Resulting From: Foreign rate differential (36 ) (51 ) Foreign exchange loss on inter-company debt refinancing (62 ) — Income tax credits (72 ) (41 ) Global intangible low-taxed income 70 32 Foreign-derived intangible income (12 ) (9 ) Singapore tax holiday (7 ) (8 ) Transition tax and other impacts of U.S. tax reform (20 ) 70 Reversal of tax reserves, net (5 ) (49 ) Excess tax benefits from stock options and restricted stock units (36 ) (25 ) Other, net 10 3 Provision for income taxes $ 2 $ 55 The company has operations and a taxable presence in approximately 50 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. In the first quarter of 2019, the company recorded a $62 million income tax benefit related to a foreign exchange loss for tax purposes on certain intercompany financing arrangements. In addition, the company recorded a net tax benefit of $27 million in the first quarter of 2019, consisting of an incremental benefit of $20 million and a $7 million reduction of related unrecognized tax benefits, to adjust the impacts of U.S. tax reform based on final regulations issued by the U.S. Treasury in January 2019. The company has significant activities in Singapore and has received considerable tax incentives. The local taxing authority granted the company pioneer company status which provides an incentive encouraging companies to undertake activities that have the effect of promoting economic or technological development in Singapore. This incentive equates to a tax exemption on earnings associated with most of the company’s manufacturing activities in Singapore and continues through December 31, 2026 . In 2019 and 2018 , the impact of this tax holiday decreased the annual effective tax rates by 0.9 percentage points and 1.3 percentage points, respectively, and increased diluted earnings per share by approximately $0.02 and $0.02 , respectively. Unrecognized Tax Benefits As of March 30, 2019 , the company had $1.43 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2019 Balance at Beginning of Year $ 1,442 Additions for tax positions of current year 2 Reductions for tax positions of prior years (7 ) Settlements (5 ) Balance at End of Period $ 1,432

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 7 . Earnings per Share Three Months Ended March 30, March 31, (In millions except per share amounts) 2019 2018 Net Income $ 815 $ 579 Basic Weighted Average Shares 400 402 Plus Effect of: Stock options and restricted units 3 4 Diluted Weighted Average Shares 403 406 Basic Earnings per Share $ 2.04 $ 1.44 Diluted Earnings per Share $ 2.02 $ 1.43 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares 2 2

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	3 Months Ended
	Mar. 30, 2019
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 8 . Debt and Other Financing Arrangements Effective Interest Rate at March 30, March 30, December 31, (Dollars in millions) 2019 2019 2018 Commercial Paper $ — $ 693 Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated) 0.10 % 561 574 6.00% 10-Year Senior Notes, Due 3/1/2020 2.97 % 750 750 4.70% 10-Year Senior Notes, Due 5/1/2020 4.23 % 300 300 Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) 0.17 % 673 688 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) 1.62 % 477 487 5.00% 10-Year Senior Notes, Due 1/15/2021 3.24 % 400 400 4.50% 10-Year Senior Notes, Due 3/1/2021 6.78 % 1,000 1,000 3.60% 10-Year Senior Notes, Due 8/15/2021 6.42 % 1,100 1,100 3.30% 7-Year Senior Notes, Due 2/15/2022 3.42 % 800 800 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.28 % 561 574 3.15% 10-Year Senior Notes, Due 1/15/2023 3.30 % 800 800 3.00% 7-Year Senior Notes, Due 4/15/2023 6.63 % 1,000 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,122 1,147 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.09 % 718 734 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 785 802 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 561 574 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 673 688 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 785 802 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 785 802 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 Other 19 21 Total Borrowings at Par Value 18,320 19,186 Fair Value Hedge Accounting Adjustments (68 ) (93 ) Unamortized Discount, Net (26 ) (21 ) Unamortized Debt Issuance Costs (78 ) (82 ) Total Borrowings at Carrying Value 18,148 18,990 Less: Short-term Obligations and Current Maturities 1,336 1,271 Long-term Obligations $ 16,812 $ 17,719 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging. See Note 12 for fair value information pertaining to the company’s long-term obligations. Credit Facilities The company has a revolving credit facility with a bank group that provides for up to $2.50 billion of unsecured multi-currency revolving credit. The facility expires in July 2021 . The agreement calls for interest at either a LIBOR-based rate, a EURIBOR-based rate (for funds drawn in Euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in our revolving credit facility (the Facility) include a Consolidated Leverage Ratio (total debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 3.5 :1.0. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0 :1.0 as of the last day of any fiscal quarter. As of March 30, 2019 , no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $87 million as a result of outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of March 30, 2019 , there were no outstanding borrowings under these programs. Senior Notes Interest on the floating rate senior notes is payable quarterly. Interest is payable annually on the other euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. In 2018, Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the company, issued the Floating Rate Senior Notes due 2020 included in the table above. This subsidiary has no independent function other than financing activities. The Floating Rate Senior Notes due 2020 are fully and unconditionally guaranteed by the company and no other subsidiaries of the company have guaranteed the obligations. Interest Rate Swap Arrangements and related Cross-currency Interest Rate Swap Arrangements The company has entered into LIBOR-based interest rate swap arrangements with various banks on several of its outstanding senior notes. The aggregate amounts of the swaps are equal to the principal amounts of the notes and the payment dates of the swaps coincide with the interest payment dates of the notes. The swap contracts provide for the company to pay a variable interest rate and receive a fixed rate. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 12 for additional information on the interest rate swap arrangements and related cross-currency interest rate swap arrangements. The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at March 30, 2019 : Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate March 30, Receive Rate 4.50% Senior Notes due 2021 (a) 1,000 1-month LIBOR + 3.4420% 5.9313 % 4.50 % 3.60% Senior Notes due 2021 1,100 1-month LIBOR + 2.5150% 4.9988 % 3.60 % 3.00% Senior Notes due 2023 (a) 1,000 1-month LIBOR + 1.7640% 4.2478 % 3.00 % (a) The payments on $1.8 billion notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of March 30, 2019 from a weighted average of 4.93% to a weighted average of 1.86% . The company has entered into $1.8 billion notional value of cross-currency interest rate swaps, which effectively convert a portion of the semi-annual payments related to the variable rate, U.S. dollar denominated, LIBOR-based interest rate swaps to payments on variable rate, euro denominated, EURIBOR-based cross-currency interest rate swaps.

Leases

Leases	3 Months Ended
	Mar. 30, 2019
Leases [Abstract]
Lessee, Operating Leases [Text Block]	Note 9 . Leases As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years , and some include options to extend (generally for 1 to 10 years ) or have options to terminate the arrangement within 1 year . The company’s finance leases are not material. The company has guaranteed the residual value of three leased operating facilities with initial lease terms ending in 2019, 2020 and 2023. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 8 ). The aggregate maximum guarantee under these three lease arrangements is $147 million . Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of March 30, 2019 , but exclude any amounts for residual value guarantees. As a lessee, the consolidated statement of income includes pre-tax operating lease costs and variable lease costs of $48 million and $9 million for the three months ended March 30, 2019 . Lease costs arising from finance leases, short-term leases, and sublease income are not material. Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities was $48 million in the three months ended March 30, 2019 . Operating lease ROU assets of $13 million were obtained in exchange for new operating lease liabilities in the three months ended March 30, 2019 . The weighted-average remaining operating lease term was 6.2 years and the weighted average discount rate was 4.0% as of March 30, 2019 . ROU assets of $600 million as of March 30, 2019 , are classified in other assets in the consolidated balance sheet. Operating lease liabilities of $156 million and $487 million as of March 30, 2019 , are classified in other accrued expenses and other long-term liabilities, respectively, in the consolidated balance sheet. As of March 30, 2019 , future payments of operating lease liabilities are as follows: (In millions) Remainder of 2019 $ 140 2020 158 2021 116 2022 84 2023 57 2024 39 2025 and Thereafter 134 Total Lease Payments 728 Less: Imputed Interest 85 Total Operating Lease Liability $ 643 As a lessor, operating leases, sales-type leases and direct financing leases are not material. As previously disclosed in the company's 2018 Annual Report on Form 10-K and under previous lease accounting guidance, the following is a summary of annual future minimum lease and rental commitments under noncancelable operating leases as of December 31, 2018 : (In millions) 2019 $ 192 2020 158 2021 118 2022 86 2023 58 2024 and Thereafter 177 $ 789

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 10 . Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At March 30, 2019 , the company’s total environmental liability was approximately $66 million . While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows. Litigation and Related Contingencies There are various lawsuits and claims pending against the company including matters involving product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below or in the company's 2018 financial statements and notes included in the company's Annual Report on Form 10-K filed with the SEC, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. Intellectual Property Matters On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product "supply centers" installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief. On August 24, 2017, Unisone filed an appeal from a decision by the Patent Trial and Appeal Board (PTAB) that found the challenged patent claims invalid. The United States Court of Appeals for the Federal Circuit upheld the PTAB’s ruling finding the challenged claims in the Unisone patent invalid. Unisone had until March 11, 2019 to file an appeal with the United States Supreme Court. Unisone did not appeal that decision, and consequently the case before the United States District Court, which had been stayed pending the outcome of the PTAB decision, will resume with respect to similar Unisone patent claims that were not included in the PTAB proceeding.

Comprehensive Income

Comprehensive Income	3 Months Ended
	Mar. 30, 2019
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 11 . Comprehensive Income Comprehensive income (loss) combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet. Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2018 $ (2,243 ) $ (52 ) $ (203 ) $ (2,498 ) Other comprehensive income (loss) before reclassifications (15 ) — 1 (14 ) Amounts reclassified from accumulated other comprehensive items — 2 1 3 Net other comprehensive items (15 ) 2 2 (11 ) Balance at March 30, 2019 $ (2,258 ) $ (50 ) $ (201 ) $ (2,509 )

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	3 Months Ended
	Mar. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 12 . Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2019 . The company’s financial assets and liabilities carried at fair value are primarily comprised of insurance contracts, investments in money market funds, derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration. The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves. Level 3: Inputs are unobservable data points that are not corroborated by market data. The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of March 30, 2019 and December 31, 2018 : March 30, Quoted Significant Significant (In millions) 2019 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 77 $ 77 $ — $ — Bank time deposits 2 2 — — Investments in common stock, mutual funds and other similar instruments 19 19 — — Warrants 6 — 6 — Insurance contracts 120 — 120 — Derivative contracts 75 — 75 — Total Assets $ 299 $ 98 $ 201 $ — Liabilities Derivative contracts $ 103 $ — $ 103 $ — Contingent consideration 37 — — 37 Total Liabilities $ 140 $ — $ 103 $ 37 December 31, Quoted Significant Significant (In millions) 2018 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 769 $ 769 $ — $ — Bank time deposits 2 2 — — Investments in mutual funds and other similar instruments 10 10 — — Warrants 8 — 8 — Insurance contracts 113 — 113 — Derivative contracts 31 — 31 — Total Assets $ 933 $ 781 $ 152 $ — Liabilities Derivative contracts $ 145 $ — $ 145 $ — Contingent consideration 37 — — 37 Total Liabilities $ 182 $ — $ 145 $ 37 The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on the probability-weighted discounted cash flows associated with such future payments. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration. Three Months Ended March 30, March 31, (In millions) 2019 2018 Contingent Consideration Beginning Balance $ 37 $ 35 Acquisitions — 11 Payments — (5 ) Ending Balance $ 37 $ 41 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. March 30, December 31, (In millions) 2019 2018 Notional Amount Interest rate swaps (described in Note 8) $ 3,100 $ 3,100 Cross-currency interest rate swaps - designated as net investment hedges 1,800 1,500 Currency exchange contracts 3,879 3,424 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income. Fair Value – Assets Fair Value – Liabilities March 30, December 31, March 30, December 31, (In millions) 2019 2018 2019 2018 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ — $ — $ 100 $ 129 Cross-currency interest rate swaps (b) 66 28 — — Derivatives Not Designated as Hedging Instruments Currency exchange contracts (c) 9 3 3 16 Total Derivatives $ 75 $ 31 $ 103 $ 145 (a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities. (b) The fair value of the cross-currency interest rate swaps is included in the consolidated balance sheet under the caption other assets. (c) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability (d) March 30, December 31, March 30, December 31, (In millions) 2019 2018 2019 2018 Long-term Obligations $ 3,317 $ 3,291 $ (68 ) $ (93 ) (d) Includes increases in the carrying amount of $27 million and $30 million at March 30, 2019 and December 31, 2018 , respectively, on discontinued hedging relationships. Gain (Loss) Recognized Three Months Ended March 30, March 31, (In millions) 2019 2018 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other expense, net $ (28 ) $ 42 Derivatives designated as hedging instruments - included in other expense, net 29 (38 ) Derivatives Designated as Cash Flow Hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to other expense, net (3 ) (3 ) Derivatives Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 156 (200 ) Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 37 — Included in other expense, net 14 — Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues 2 (2 ) Included in other expense, net 17 (8 ) Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company also uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The majority of the company’s euro-denominated senior notes and cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. See Note 1 to the consolidated financial statements for 2018 included in the company's Annual Report on Form 10-K and Note 8 herein for additional information on the company's risk management objectives and strategies. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: March 30, 2019 December 31, 2018 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 18,129 $ 18,781 $ 18,276 $ 18,322 Commercial paper — — 693 693 Other 19 19 21 21 $ 18,148 $ 18,800 $ 18,990 $ 19,036 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 30, 2019
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 13 . Supplemental Cash Flow Information Three Months Ended March 30, March 31, (In millions) 2019 2018 Non-cash Investing and Financing Activities Declared but unpaid dividends $ 77 $ 69 Issuance of stock upon vesting of restricted stock units 69 61 Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: March 30, December 31, (In millions) 2019 2018 Cash and Cash Equivalents $ 1,106 $ 2,103 Restricted Cash Included in Other Current Assets 21 12 Restricted Cash Included in Other Assets 1 2 Cash, Cash Equivalents and Restricted Cash $ 1,128 $ 2,117 Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Restructuring and Other Costs,

Restructuring and Other Costs, Net	3 Months Ended
	Mar. 30, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 14 . Restructuring and Other Costs, Net Restructuring and other costs, net, in the first three months of 2019 included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S. and Europe; third-party transaction/integration costs related to recently announced acquisitions and divestiture; and sales of inventories revalued at the date of acquisition. In the first three months of 2019 , severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce. As of May 3, 2019 , the company has identified restructuring actions that will result in additional charges of approximately $65 million , primarily in 2019 and 2020, and expects to identify additional actions during 2019 which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. First Three Months of 2019 During the first three months of 2019 , the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 6 $ — $ 3 $ 9 Analytical Instruments — 6 4 10 Specialty Diagnostics — 4 1 5 Laboratory Products and Services — 1 2 3 Corporate — — 1 1 $ 6 $ 11 $ 11 $ 28 The principal components of net restructuring and other costs by segment are as follows: Life Sciences Solutions In the first three months of 2019 , the Life Sciences Solutions segment recorded $9 million of net restructuring and other costs, principally charges to cost of revenues of $6 million for the sales of inventory revalued at the date of acquisition. The segment also recorded $3 million of charges for severance and other costs associated with facility consolidations in the U.S. and Europe. Analytical Instruments In the first three months of 2019 , the Analytical Instruments segment recorded $10 million of net restructuring and other charges, including $6 million of charges to selling, general, and administrative expense for third-party transaction costs related to the pending acquisition of Gatan. The segment also recorded $4 million of restructuring and other costs, primarily for employee severance and other costs associated with facility consolidations in the U.S. and Europe. Specialty Diagnostics In the first three months of 2019 , the Specialty Diagnostics segment recorded $5 million of net restructuring and other charges, principally $4 million of charges to selling, general, and administrative expense for third-party transaction costs in connection with the planned sale of the Anatomical Pathology business. The segment also recorded $1 million of charges for severance and other costs associated with facility consolidations in the U.S. and Europe. Laboratory Products and Services In the first three months of 2019 , the Laboratory Products and Services segment recorded $3 million of net restructuring and other charges. The segment recorded $1 million of charges to selling, general, and administrative expense for third-party transaction costs related to the acquisition of Brammer Bio. The segment also recorded $2 million of restructuring and other costs, primarily for employee severance. Corporate In the first three months of 2019 , the company recorded $1 million of net restructuring and other costs for severance at its corporate operations. The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Severance Abandonment of Excess Facilities Other (a) Total Balance at December 31, 2018 $ 34 $ 42 $ 4 $ 80 Cumulative effect of accounting change (b) — (28 ) — (28 ) Costs incurred in 2019 8 — 3 11 Reserves reversed (c) (1 ) — — (1 ) Payments (7 ) (4 ) (3 ) (14 ) Balance at March 30, 2019 $ 34 $ 10 $ 4 $ 48 (a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Impact of adopting new lease accounting guidance on January 1, 2019. (c) Represents reductions in cost of plans. The company expects to pay accrued restructuring costs primarily through 2019 .

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Lessee, Leases [Policy Text Block]	Leases The company determines whether an arrangement is, or contains, a lease at inception. Prior to 2019, the company generally accounted for operating lease payments by charging them to expense as incurred. Beginning in 2019, operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Classification of operating lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes lease expense for these leases on a straight-line basis over the lease term. Because most of the company’s leases do not provide an implicit rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms may include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2 ) and the ultimate loss from abandoning leases at facilities being exited (Note 14 ). Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company expects to adopt the guidance when it is effective in 2020 using a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company expects to adopt the guidance when it is effective in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018, the FASB issued additional guidance and clarification. The company expects to adopt the guidance when it is effective in 2020 using a modified retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. During 2017 - 2019, the FASB issued additional guidance and clarification. The guidance became effective for the company in 2019. The company has elected to adopt the guidance using a modified retrospective method, by applying the transition approach as of the beginning of the period of adoption. Comparative periods have not been restated. As permitted upon transition, the company did not reassess whether any expired or existing contracts were or contained embedded leases, the lease classification for any expired or existing leases, initial direct costs for any leases, or whether land easements met the definition of a lease if they were not accounted for as leases under the prior guidance. Adoption of the new guidance impacted the company’s Consolidated Balance Sheet as follows: (In millions) December 31, Impact of Adopting New Lease Guidance January 1, Other Assets $ 1,117 $ 641 $ 1,758 Other Accrued Expenses 1,470 132 1,602 Other Long-term Liabilities 2,515 505 3,020 Retained Earnings 18,696 4 18,700
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Acquisitions and Dispositions (

Acquisitions and Dispositions (Policies)	3 Months Ended
	Mar. 30, 2019
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract with Customer, Asset and Liability [Table Text Block]	Contract asset and liability balances are as follows: March 30, December 31, (In millions) 2019 2018 Current Contract Assets, Net $ 545 $ 459 Noncurrent Contract Assets, Net 15 15 Current Contract Liabilities 967 809 Noncurrent Contract Liabilities 497 355
Warranty Obligations [Table Text Block]	Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Three Months Ended March 30, March 31, (In millions) 2019 2018 Beginning Balance $ 92 $ 87 Provision charged to income 27 31 Usage (28 ) (28 ) Adjustments to previously provided warranties, net (1 ) (1 ) Currency translation — 1 Ending Balance $ 90 $ 90
Inventories [Table Text Block]	Inventories The components of inventories are as follows: March 30, December 31, (In millions) 2019 2018 Raw Materials $ 867 $ 812 Work in Process 472 430 Finished Goods 1,785 1,763 Inventories $ 3,124 $ 3,005
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	(In millions) December 31, Impact of Adopting New Lease Guidance January 1, Other Assets $ 1,117 $ 641 $ 1,758 Other Accrued Expenses 1,470 132 1,602 Other Long-term Liabilities 2,515 505 3,020 Retained Earnings 18,696 4 18,700

Acquisitions and Dispositions_2

Acquisitions and Dispositions (Tables)	3 Months Ended
	Mar. 30, 2019
Business Combinations [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	(In millions) March 30, 2019 Current Assets $ 85 Long-term Assets 540 Current Liabilities 32 Long-term Liabilities 33

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 30, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregated Revenue Revenue by type is as follows: Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues Consumables $ 3,230 3,111 Instruments 1,490 1,417 Services 1,405 1,325 Consolidated revenues $ 6,125 $ 5,853 Revenue by geographic region is as follows: Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues (a) North America $ 3,059 $ 2,903 Europe 1,519 1,518 Asia-Pacific 1,363 1,264 Other regions 184 168 Consolidated revenues $ 6,125 $ 5,853

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	3 Months Ended
	Mar. 30, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues Life Sciences Solutions $ 1,607 $ 1,499 Analytical Instruments 1,322 1,257 Specialty Diagnostics 957 947 Laboratory Products and Services 2,513 2,413 Eliminations (274 ) (263 ) Consolidated revenues 6,125 5,853 Segment Income (a) Life Sciences Solutions 561 517 Analytical Instruments 282 246 Specialty Diagnostics 242 243 Laboratory Products and Services 285 280 Subtotal reportable segments (a) 1,370 1,286 Cost of revenues charges, net (6 ) (3 ) Selling, general and administrative charges, net (11 ) (8 ) Restructuring and other costs, net (11 ) (45 ) Amortization of acquisition-related intangible assets (422 ) (444 ) Consolidated operating income 920 786 Other expense, net (b) (103 ) (152 ) Income from continuing operations before income taxes $ 817 $ 634 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues Life Sciences Solutions $ 1,607 $ 1,499 Analytical Instruments 1,322 1,257 Specialty Diagnostics 957 947 Laboratory Products and Services 2,513 2,413 Eliminations (274 ) (263 ) Consolidated revenues 6,125 5,853 Segment Income (a) Life Sciences Solutions 561 517 Analytical Instruments 282 246 Specialty Diagnostics 242 243 Laboratory Products and Services 285 280 Subtotal reportable segments (a) 1,370 1,286 Cost of revenues charges, net (6 ) (3 ) Selling, general and administrative charges, net (11 ) (8 ) Restructuring and other costs, net (11 ) (45 ) Amortization of acquisition-related intangible assets (422 ) (444 ) Consolidated operating income 920 786 Other expense, net (b) (103 ) (152 ) Income from continuing operations before income taxes $ 817 $ 634 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Geographical Information Three Months Ended March 30, March 31, (In millions) 2019 2018 Revenues (c) United States $ 2,918 $ 2,756 China 654 541 Other 2,553 2,556 Consolidated revenues $ 6,125 $ 5,853 (c) Revenues are attributed to countries based on customer location.

Other Expense, Net (Tables)

Other Expense, Net (Tables)	3 Months Ended
	Mar. 30, 2019
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	The components of other expense, net, in the accompanying statement of income are as follows: Three Months Ended March 30, March 31, (In millions) 2019 2018 Interest Income $ 67 $ 20 Interest Expense (189 ) (163 ) Other Items, Net 19 (9 ) Other Expense, Net $ (103 ) $ (152 )

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 30, 2019
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Three Months Ended March 30, March 31, (In millions) 2019 2018 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 172 $ 133 Increases (Decreases) Resulting From: Foreign rate differential (36 ) (51 ) Foreign exchange loss on inter-company debt refinancing (62 ) — Income tax credits (72 ) (41 ) Global intangible low-taxed income 70 32 Foreign-derived intangible income (12 ) (9 ) Singapore tax holiday (7 ) (8 ) Transition tax and other impacts of U.S. tax reform (20 ) 70 Reversal of tax reserves, net (5 ) (49 ) Excess tax benefits from stock options and restricted stock units (36 ) (25 ) Other, net 10 3 Provision for income taxes $ 2 $ 55
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2019 Balance at Beginning of Year $ 1,442 Additions for tax positions of current year 2 Reductions for tax positions of prior years (7 ) Settlements (5 ) Balance at End of Period $ 1,432

Earnings per Share (Tables)

Earnings per Share (Tables)	3 Months Ended
	Mar. 30, 2019
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 30, March 31, (In millions except per share amounts) 2019 2018 Net Income $ 815 $ 579 Basic Weighted Average Shares 400 402 Plus Effect of: Stock options and restricted units 3 4 Diluted Weighted Average Shares 403 406 Basic Earnings per Share $ 2.04 $ 1.44 Diluted Earnings per Share $ 2.02 $ 1.43 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares 2 2

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	3 Months Ended
	Mar. 30, 2019
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective Interest Rate at March 30, March 30, December 31, (Dollars in millions) 2019 2019 2018 Commercial Paper $ — $ 693 Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated) 0.10 % 561 574 6.00% 10-Year Senior Notes, Due 3/1/2020 2.97 % 750 750 4.70% 10-Year Senior Notes, Due 5/1/2020 4.23 % 300 300 Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) 0.17 % 673 688 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) 1.62 % 477 487 5.00% 10-Year Senior Notes, Due 1/15/2021 3.24 % 400 400 4.50% 10-Year Senior Notes, Due 3/1/2021 6.78 % 1,000 1,000 3.60% 10-Year Senior Notes, Due 8/15/2021 6.42 % 1,100 1,100 3.30% 7-Year Senior Notes, Due 2/15/2022 3.42 % 800 800 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.28 % 561 574 3.15% 10-Year Senior Notes, Due 1/15/2023 3.30 % 800 800 3.00% 7-Year Senior Notes, Due 4/15/2023 6.63 % 1,000 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,122 1,147 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.09 % 718 734 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 785 802 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 561 574 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 673 688 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 785 802 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 785 802 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 Other 19 21 Total Borrowings at Par Value 18,320 19,186 Fair Value Hedge Accounting Adjustments (68 ) (93 ) Unamortized Discount, Net (26 ) (21 ) Unamortized Debt Issuance Costs (78 ) (82 ) Total Borrowings at Carrying Value 18,148 18,990 Less: Short-term Obligations and Current Maturities 1,336 1,271 Long-term Obligations $ 16,812 $ 17,719
Schedule of Derivative Instruments [Table Text Block]	Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate March 30, Receive Rate 4.50% Senior Notes due 2021 (a) 1,000 1-month LIBOR + 3.4420% 5.9313 % 4.50 % 3.60% Senior Notes due 2021 1,100 1-month LIBOR + 2.5150% 4.9988 % 3.60 % 3.00% Senior Notes due 2023 (a) 1,000 1-month LIBOR + 1.7640% 4.2478 % 3.00 %

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 30, 2019
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	of operating lease liabilities are as follows: (In millions) Remainder of 2019 $ 140 2020 158 2021 116 2022 84 2023 57 2024 39 2025 and Thereafter 134 Total Lease Payments 728 Less: Imputed Interest 85 Total Operating Lease Liability $ 643
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	As previously disclosed in the company's 2018 Annual Report on Form 10-K and under previous lease accounting guidance, the following is a summary of annual future minimum lease and rental commitments under noncancelable operating leases as of December 31, 2018 : (In millions) 2019 $ 192 2020 158 2021 118 2022 86 2023 58 2024 and Thereafter 177 $ 789

Comprehensive Income (Tables)

Comprehensive Income (Tables)	3 Months Ended
	Mar. 30, 2019
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2018 $ (2,243 ) $ (52 ) $ (203 ) $ (2,498 ) Other comprehensive income (loss) before reclassifications (15 ) — 1 (14 ) Amounts reclassified from accumulated other comprehensive items — 2 1 3 Net other comprehensive items (15 ) 2 2 (11 ) Balance at March 30, 2019 $ (2,258 ) $ (50 ) $ (201 ) $ (2,509 )

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of March 30, 2019 and December 31, 2018 : March 30, Quoted Significant Significant (In millions) 2019 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 77 $ 77 $ — $ — Bank time deposits 2 2 — — Investments in common stock, mutual funds and other similar instruments 19 19 — — Warrants 6 — 6 — Insurance contracts 120 — 120 — Derivative contracts 75 — 75 — Total Assets $ 299 $ 98 $ 201 $ — Liabilities Derivative contracts $ 103 $ — $ 103 $ — Contingent consideration 37 — — 37 Total Liabilities $ 140 $ — $ 103 $ 37 December 31, Quoted Significant Significant (In millions) 2018 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 769 $ 769 $ — $ — Bank time deposits 2 2 — — Investments in mutual funds and other similar instruments 10 10 — — Warrants 8 — 8 — Insurance contracts 113 — 113 — Derivative contracts 31 — 31 — Total Assets $ 933 $ 781 $ 152 $ — Liabilities Derivative contracts $ 145 $ — $ 145 $ — Contingent consideration 37 — — 37 Total Liabilities $ 182 $ — $ 145 $ 37
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	he following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration. Three Months Ended March 30, March 31, (In millions) 2019 2018 Contingent Consideration Beginning Balance $ 37 $ 35 Acquisitions — 11 Payments — (5 ) Ending Balance $ 37 $ 41
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	he following table provides the aggregate notional value of outstanding derivative contracts. March 30, December 31, (In millions) 2019 2018 Notional Amount Interest rate swaps (described in Note 8) $ 3,100 $ 3,100 Cross-currency interest rate swaps - designated as net investment hedges 1,800 1,500 Currency exchange contracts 3,879 3,424
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value – Assets Fair Value – Liabilities March 30, December 31, March 30, December 31, (In millions) 2019 2018 2019 2018 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ — $ — $ 100 $ 129 Cross-currency interest rate swaps (b) 66 28 — — Derivatives Not Designated as Hedging Instruments Currency exchange contracts (c) 9 3 3 16 Total Derivatives $ 75 $ 31 $ 103 $ 145 (a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities. (b) The fair value of the cross-currency interest rate swaps is included in the consolidated balance sheet under the caption other assets. (c) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability (d) March 30, December 31, March 30, December 31, (In millions) 2019 2018 2019 2018 Long-term Obligations $ 3,317 $ 3,291 $ (68 ) $ (93 ) (d) Includes increases in the carrying amount of $27 million and $30 million at March 30, 2019 and December 31, 2018 , respectively, on discontinued hedging relationships.
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (Loss) Recognized Three Months Ended March 30, March 31, (In millions) 2019 2018 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other expense, net $ (28 ) $ 42 Derivatives designated as hedging instruments - included in other expense, net 29 (38 ) Derivatives Designated as Cash Flow Hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to other expense, net (3 ) (3 ) Derivatives Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 156 (200 ) Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 37 — Included in other expense, net 14 — Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues 2 (2 ) Included in other expense, net 17 (8 )
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: March 30, 2019 December 31, 2018 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 18,129 $ 18,781 $ 18,276 $ 18,322 Commercial paper — — 693 693 Other 19 19 21 21 $ 18,148 $ 18,800 $ 18,990 $ 19,036 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: March 30, 2019 December 31, 2018 Carrying Fair Carrying Fair (In millions) Value Value Value Value Debt Obligations: Senior notes $ 18,129 $ 18,781 $ 18,276 $ 18,322 Commercial paper — — 693 693 Other 19 19 21 21 $ 18,148 $ 18,800 $ 18,990 $ 19,036 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 30, 2019
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Three Months Ended March 30, March 31, (In millions) 2019 2018 Non-cash Investing and Financing Activities Declared but unpaid dividends $ 77 $ 69 Issuance of stock upon vesting of restricted stock units 69 61
Restrictions on Cash and Cash Equivalents [Table Text Block]	Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: March 30, December 31, (In millions) 2019 2018 Cash and Cash Equivalents $ 1,106 $ 2,103 Restricted Cash Included in Other Current Assets 21 12 Restricted Cash Included in Other Assets 1 2 Cash, Cash Equivalents and Restricted Cash $ 1,128 $ 2,117

Restructuring and Other Costs_2

Restructuring and Other Costs, Net (Tables)	3 Months Ended
	Mar. 30, 2019
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	During the first three months of 2019 , the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 6 $ — $ 3 $ 9 Analytical Instruments — 6 4 10 Specialty Diagnostics — 4 1 5 Laboratory Products and Services — 1 2 3 Corporate — — 1 1 $ 6 $ 11 $ 11 $ 28
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Severance Abandonment of Excess Facilities Other (a) Total Balance at December 31, 2018 $ 34 $ 42 $ 4 $ 80 Cumulative effect of accounting change (b) — (28 ) — (28 ) Costs incurred in 2019 8 — 3 11 Reserves reversed (c) (1 ) — — (1 ) Payments (7 ) (4 ) (3 ) (14 ) Balance at March 30, 2019 $ 34 $ 10 $ 4 $ 48 (a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Impact of adopting new lease accounting guidance on January 1, 2019. (c) Represents reductions in cost of plans.

Contract Assets and Liabilities

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Dec. 31, 2018
Contract with Customer, Asset and Liability [Abstract]
Current Contract Assets, Net	$ 545	$ 459
Noncurrent Contract Asset, Net	15	15
Current Contract Liabilities	967	809
Noncurrent Contract Liabilities	497	$ 355
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 336

Warranty Obligations (Details)

Warranty Obligations (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Warranty Obligations [Roll Forward]
Beginning Balance	$ 92	$ 87
Provision charged to income	27	31
Usage	(28)	(28)
Adjustments to previously provided warranties, net	(1)	(1)
Currency translation		1
Ending Balance	$ 90	$ 90

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Mar. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw Materials	$ 867	$ 812
Work in Process	472	430
Finished Goods	1,785	1,763
Inventories	$ 3,124	$ 3,005

Recent Accounting Pronouncement

Recent Accounting Pronouncements (Details) - USD ($) $ in Millions	Mar. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other Assets	$ 1,740	$ 1,758	$ 1,117
Other accrued expenses	1,429	1,602	1,470
Other Long-term Liabilities	3,048	3,020	2,515
Retained earnings	$ 19,439	18,700	$ 18,696
Impact of Adopting New Lease Guidance [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other Assets		641
Other accrued expenses		132
Other Long-term Liabilities		505
Retained earnings		$ 4

Acquisitions Purchase Price (De

Acquisitions Purchase Price (Details) - USD ($) $ in Millions	3 Months Ended	8 Months Ended	12 Months Ended
	Jun. 29, 2019	Dec. 31, 2019	Dec. 31, 2018
Brammer Bio [Member]
Net Assets Acquired [Abstract]
Revenue Reported by Acquired Entity			$ 140
Scenario, Forecast [Member] | Brammer Bio [Member]
Purchase Price
Cash paid	$ 1,700
Scenario, Forecast [Member] | Gatan, Inc. [Member]
Purchase Price
Cash paid		$ 925

Acquisitions and Dispositions D

Acquisitions and Dispositions Dispositions (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 30, 2019	Mar. 31, 2018	Dec. 31, 2018	Jun. 29, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	$ 6,125	$ 5,853
Current Assets	9,939		$ 10,625
Current Liabilities	5,898		6,147
Anatomical Pathology business [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	85		$ 344
Current Assets	85
Long-term Assets	540
Current Liabilities	32
Long-term Liabilities	$ 33
Scenario, Forecast [Member] | Anatomical Pathology business [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration				$ 1,140

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 30, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Revenues		$ 6,125	$ 5,853
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	3,059	2,903
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	1,519	1,518
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	1,363	1,264
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	184	168
Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues		3,230	3,111
Instruments [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,490	1,417
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues		$ 1,405	$ 1,325
[1]	Revenues are attributed to regions based on customer location.

Revenue Performance Obligations

Revenue Performance Obligations (Details) $ in Millions	Mar. 30, 2019USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 5,570
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-03-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Percentage	85.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 30, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Revenues		$ 6,125	$ 5,853
Cost of revenues charges, net		(6)
Selling, general and administrative charges, net		(11)
Restructuring and other costs, net		(11)	(45)
Amortization of acquisition-related intangible assets		(422)	(444)
Operating Income		920	786
Other expense, net		(103)	(152)
Income from Continuing Operations Before Income Taxes		817	634
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges, net		(6)
Restructuring and other costs, net		(3)
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative charges, net		(6)
Restructuring and other costs, net		(4)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative charges, net		(4)
Restructuring and other costs, net		(1)
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative charges, net		(1)
Restructuring and other costs, net		(2)
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income	[1]	1,370	1,286
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues		1,607	1,499
Operating Income	[1]	561	517
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues		1,322	1,257
Operating Income	[1]	282	246
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues		957	947
Operating Income	[1]	242	243
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues		2,513	2,413
Operating Income	[1]	285	280
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues		(274)	(263)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges, net		(6)	(3)
Selling, general and administrative charges, net		(11)	(8)
Restructuring and other costs, net		(11)	(45)
Amortization of acquisition-related intangible assets		$ (422)	$ (444)
[1]	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

Geographical Information (Detai

Geographical Information (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 30, 2019	Mar. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 6,125	$ 5,853
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	2,918	2,756
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	654	541
All Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 2,553	$ 2,556
[1]	Revenues are attributed to countries based on customer location.

Other Expense, Net (Details)

Other Expense, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Other Income and Expenses [Abstract]
Interest Income	$ 67	$ 20
Interest Expense	(189)	(163)
Other Items, Net	19	(9)
Other Expense, Net	$ (103)	$ (152)

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory Federal Income Tax Rate	21.00%	21.00%
Provision for Income Taxes at Statutory Rate	$ 172	$ 133
Foreign rate differential	(36)	(51)
Foreign exchange loss on inter-company debt refinancing	(62)
Income tax credits	(72)	(41)
Global intangible low-taxed income	70	32
Foreign-derived intangible income	(12)	(9)
Singapore tax holiday	(7)	(8)
Transition tax and other impacts of U.S. tax reform	(20)	70
Reversal of tax reserves, net	(5)	(49)
Excess tax benefits from stock options and restricted stock units	(36)	(25)
Other, net	10	3
Provision for income taxes	2	$ 55
Tax Cuts And Jobs Act of 2017, Income Tax Expense (Benefit)	$ (27)
Singapore
Income Tax Holiday [Line Items]
Income Tax Holiday, Termination Date	12/31/2026
Effective Income Tax Rate Reconciliation, Tax Holiday, Percent	0.90%	1.30%
Income Tax Holiday, Income Tax Benefits Per Share	$ 0.02	$ 0.02

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	3 Months Ended
	Mar. 30, 2019USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of year	$ 1,442
Additions for tax positions of current year	2
Reductions for tax positions of prior years	(7)
Settlements	(5)
Balance at end of year	$ 1,432

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Income	$ 815	$ 579
Basic Weighted Average Shares	400	402
Effect of Stock Options and Restricted Units	3	4
Diluted Weighted Average Shares	403	406
Basic Earnings per Share:
Basic Earnings Per Share (in dollars per share)	$ 2.04	$ 1.44
Diluted Earnings per Share:
Diluted Earnings Per Share (in dollars per share)	$ 2.02	$ 1.43
Employee Stock Option [Member]
Diluted Earnings per Share:
Antidilutive Stock Options Excluded From Computation Of Earnings Per Share	2	2

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total Borrowings at Par Value	$ 18,320	$ 19,186
Fair Value Hedge Accounting Adjustments	(68)	(93)
Unamortized Discount, Net	(26)	(21)
Unamortized Debt Issuance Costs	(78)	(82)
Total Borrowings at Carrying Value	18,148	18,990
Less: Short-term Obligations and Current Maturities	1,336	1,271
Long-term Obligations	16,812	17,719
Commercial Paper Programs [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value		693
Total Borrowings at Carrying Value		693
Senior Notes [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value	$ 18,129	18,276
Debt Instrument, Call Feature	Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest.
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Jul. 24, 2019
Effective Interest Rate	0.10%
Total Borrowings at Par Value	$ 561	574
Senior Notes [Member] | 6.00% 10-Year Senior Notes, Due 3/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	6.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 1, 2020
Effective Interest Rate	2.97%
Total Borrowings at Par Value	$ 750	750
Senior Notes [Member] | 4.70% 10-Year Senior Notes, Due 5/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.70%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	May 1, 2020
Effective Interest Rate	4.23%
Total Borrowings at Par Value	$ 300	300
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Aug. 7, 2020
Effective Interest Rate	0.17%
Total Borrowings at Par Value	$ 673	688
Senior Notes [Member] | 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.50%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Dec. 1, 2020
Effective Interest Rate	1.62%
Total Borrowings at Par Value	$ 477	487
Senior Notes [Member] | 5.00% 10-Year Senior Notes, Due 1/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Jan. 15, 2021
Effective Interest Rate	3.24%
Total Borrowings at Par Value	$ 400	400
Senior Notes [Member] | 4.50% 10-Year Senior Notes, Due 3/1/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.50%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 1, 2021
Effective Interest Rate	6.78%
Total Borrowings at Par Value	$ 1,000	1,000
Senior Notes [Member] | 3.60% 10-Year Senior Notes, Due 8/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.60%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2021
Effective Interest Rate	6.42%
Total Borrowings at Par Value	$ 1,100	1,100
Senior Notes [Member] | 3.30% 7-Year Senior Notes, Due 2/15/2022 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.30%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Feb. 15, 2022
Effective Interest Rate	3.42%
Total Borrowings at Par Value	$ 800	800
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Jul. 21, 2022
Effective Interest Rate	2.28%
Total Borrowings at Par Value	$ 561	574
Senior Notes [Member] | 3.15% 10-Year Senior Notes, Due 1/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Jan. 15, 2023
Effective Interest Rate	3.30%
Total Borrowings at Par Value	$ 800	800
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.00%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2023
Effective Interest Rate	6.63%
Total Borrowings at Par Value	$ 1,000	1,000
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Feb. 1, 2024
Effective Interest Rate	4.16%
Total Borrowings at Par Value	$ 1,000	1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.75%
Debt Instrument, Term	8 years
Debt Instrument, Maturity Date	Sep. 12, 2024
Effective Interest Rate	0.94%
Total Borrowings at Par Value	$ 1,122	1,147
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Apr. 15, 2025
Effective Interest Rate	2.09%
Total Borrowings at Par Value	$ 718	734
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.65%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Effective Interest Rate	3.77%
Total Borrowings at Par Value	$ 350	350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.40%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Jan. 23, 2026
Effective Interest Rate	1.53%
Total Borrowings at Par Value	$ 785	802
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.95%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Sep. 19, 2026
Effective Interest Rate	3.19%
Total Borrowings at Par Value	$ 1,200	1,200
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.45%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 16, 2027
Effective Interest Rate	1.65%
Total Borrowings at Par Value	$ 561	574
Senior Notes [Member] | 3.20% 10-Year Senior Notes, Due 8/15/2027 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2027
Effective Interest Rate	3.39%
Total Borrowings at Par Value	$ 750	750
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Sep. 12, 2028
Effective Interest Rate	1.46%
Total Borrowings at Par Value	$ 673	688
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.95%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Jul. 24, 2029
Effective Interest Rate	2.08%
Total Borrowings at Par Value	$ 785	802
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.875%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Jul. 24, 2037
Effective Interest Rate	2.94%
Total Borrowings at Par Value	$ 785	802
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.30%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Feb. 1, 2044
Effective Interest Rate	5.37%
Total Borrowings at Par Value	$ 400	400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.10%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Aug. 15, 2047
Effective Interest Rate	4.23%
Total Borrowings at Par Value	$ 750	750
Other Debt [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value	19	21
Total Borrowings at Carrying Value	$ 19	$ 21

Debt Short-term Financing (Deta

Debt Short-term Financing (Details)	3 Months Ended
	Mar. 30, 2019USD ($)
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA	3.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Maximum Borrowing Capacity	$ 2,500,000,000
Line of Credit Facility, Expiration Date	Jul. 1, 2021
Letters of Credit Outstanding, Amount	$ 87,000,000
Line of Credit Facility, Amount Outstanding	$ 0
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days

Debt, Interest Rate Swap Arrang

Debt, Interest Rate Swap Arrangements (Details) - USD ($) $ in Millions		Mar. 30, 2019	Dec. 31, 2018
Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 3,100	$ 3,100
Interest Rate Swap, Pay Rate at Period End		4.93%
Cross Currency Interest Rate Contract [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,800	$ 1,500
Interest Rate Swap, Pay Rate at Period End		1.86%
Senior Notes [Member] | 4.50% Senior Notes Due 2021 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	[1]	$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		3.442%
Interest Rate Swap, Pay Rate at Period End	[1]	5.9313%
Interest Rate Swap, Fixed Receive Rate		4.50%
Senior Notes [Member] | 3.60% Senior Notes Due 2021 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,100
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		2.515%
Interest Rate Swap, Pay Rate at Period End		4.9988%
Interest Rate Swap, Fixed Receive Rate		3.60%
Senior Notes [Member] | 3.00% Senior Notes Due 2023 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	[1]	$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		1.764%
Interest Rate Swap, Pay Rate at Period End	[1]	4.2478%
Interest Rate Swap, Fixed Receive Rate		3.00%
[1]	The payments on $1.8 billion notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of March 30, 2019 from a weighted average of 4.93% to a weighted average of 1.86%.

Leases (Details)

Leases (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Operating Lease, Cost	$ 48
Variable Lease, Cost	9
Operating Lease, Payments	48
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 13
Operating Lease, Weighted Average Remaining Lease Term	6 years 2 months
Operating Lease, Weighted Average Discount Rate, Percent	4.00%
Operating Lease, Right-of-Use Asset	$ 600
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent
Operating Lease, Liability, Current	$ 156
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent
Operating Lease, Liability, Noncurrent	$ 487
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesNoncurrent
Operating Lease Liabilities, Payments Due [Abstract]
Remainder of 2019	$ 140
2020	158
2021	116
2022	84
2023	57
2024	39
2025 and Thereafter	134
Total Lease Payments	728
Less: Imputed Interest	85
Total Operating Lease Liability	$ 643
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2019		$ 192
2020		158
2021		118
2022		86
2023		58
2024 and Thereafter		177
Operating Leases, Future Minimum Payments Due		$ 789
Minimum [Member]
Lessee, Lease, Description [Line Items]
Remaining Lease Term, Operating Leases	1 month
Lessee, Operating Lease, Renewal Term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Remaining Lease Term, Operating Leases	30 years
Lessee, Operating Lease, Renewal Term	10 years
Lessee, Operating Lease, Option to Terminate, Term	1 year
Guarantee Type, Other [Member]
Lessee, Lease, Description [Line Items]
Maximum Residual Value Guarantee	$ 147

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 30, 2019USD ($)
Accrual for Environmental Loss Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Net	$ 66

Comprehensive Income (Details)

Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 27,586	$ 25,413
Other comprehensive income (loss) before reclassifications	(14)
Amounts reclassified from accumulated other comprehensive items	3
Total other comprehensive items	(11)	49
Balance	27,693	26,123
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,243)
Other comprehensive income (loss) before reclassifications	(15)
Total other comprehensive items	(15)
Balance	(2,258)
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(52)
Amounts reclassified from accumulated other comprehensive items	2
Total other comprehensive items	2
Balance	(50)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(203)
Other comprehensive income (loss) before reclassifications	1
Amounts reclassified from accumulated other comprehensive items	1
Total other comprehensive items	2
Balance	(201)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,498)	(2,003)
Total other comprehensive items	(11)	49
Balance	$ (2,509)	$ (2,042)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Mar. 30, 2019	Dec. 31, 2018
Assets [Abstract]
Cash equivalents	$ 77	$ 769
Bank time deposits	2	2
Investments in common stock, mutual funds and other similar instruments	19	10
Warrants	6	8
Insurance contracts	120	113
Derivative contracts	75	31
Total Assets	299	933
Liabilities [Abstract]
Derivative contracts	103	145
Contingent consideration	37	37
Total Liabilities	140	182
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	77	769
Bank time deposits	2	2
Investments in common stock, mutual funds and other similar instruments	19	10
Total Assets	98	781
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	6	8
Insurance contracts	120	113
Derivative contracts	75	31
Total Assets	201	152
Liabilities [Abstract]
Derivative contracts	103	145
Total Liabilities	103	145
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	37	37
Total Liabilities	$ 37	$ 37

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 37	$ 35
Acquisitions	0	11
Payments	0	(5)
Ending Balance	$ 37	$ 41

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Mar. 30, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	$ (68)	$ (93)
Long-term Obligations [Member]
Derivatives, Fair Value [Line Items]
Hedged Liability, Fair Value Hedge	3,317	3,291
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	(68)	(93)
Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)	27	30
Interest Rate Swaps [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	3,100	3,100
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	100	129
Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	1,800	1,500
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	66	28
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	3,879	3,424
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	9	3
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	3	16
Fair Value, Measurements, Recurring [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	75	31
Derivative Liabilities	$ 103	$ 145

Fair Value Measurements, Deri_2

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Currency Exchange Contracts [Member] | Cost of Product Revenues [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 2	$ (2)
Currency Exchange Contracts [Member] | Other Expense, Net [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	17	(8)
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Hedged Debt in Fair Value Hedge	(28)	42
Gain (Loss) on Derivative, Net	29	(38)
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(3)	(3)
Net Investment Hedging [Member] | Foreign currency-denominated debt [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	156	$ (200)
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	37
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Other Expense, Net [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 14

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Mar. 30, 2019	Dec. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	$ 18,148	$ 18,990
Debt Instrument, Fair Value Disclosure	18,800	19,036
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	18,129	18,276
Debt Instrument, Fair Value Disclosure	18,781	18,322
Commercial Paper Programs [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value		693
Debt Instrument, Fair Value Disclosure		693
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	19	21
Debt Instrument, Fair Value Disclosure	$ 19	$ 21

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Non-cash Investing and Financing Activities [Abstract]
Declared but unpaid dividends	$ 77	$ 69
Issuance of stock upon vesting of restricted stock units	69	61
Cash and Cash Equivalents	1,106		$ 2,103
Restricted Cash Included in Other Current Assets	21		12
Restricted Cash Included in Other Assets	1		2
Cash, Cash Equivalents and Restricted Cash	$ 1,128	$ 975	$ 2,117	$ 1,361
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsCurrent
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent

Restructuring and Other Costs_3

Restructuring and Other Costs, Net (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 30, 2019	Mar. 31, 2018	May 04, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated		1.00%
Cost of Revenues		$ 6
Selling, General and Administrative Expenses		11
Restructuring and other costs, net		11	$ 45
Total Restructuring and Other Costs (Income), Net		28
Restructuring and Related Costs, Cash Costs		11
Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs		8
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	[1]	3
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		6
Restructuring and other costs, net		3
Total Restructuring and Other Costs (Income), Net		9
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		6
Restructuring and other costs, net		4
Total Restructuring and Other Costs (Income), Net		10
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		4
Restructuring and other costs, net		1
Total Restructuring and Other Costs (Income), Net		5
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		1
Restructuring and other costs, net		2
Total Restructuring and Other Costs (Income), Net		3
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net		1
Total Restructuring and Other Costs (Income), Net		$ 1
Scenario, Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs				$ 65
[1]	Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Restructuring Reserves (Details

Restructuring Reserves (Details) $ in Millions	3 Months Ended
	Mar. 30, 2019USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 80
Cumulative Effect of Accounting Change	(28)	[1]
Costs incurred	11
Reserves reversed	(1)	[2]
Payments	(14)
Ending balance	$ 48
Restructuring Reserve, Expected Final Year of Payments	2019
Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	$ 34
Costs incurred	8
Reserves reversed	(1)	[2]
Payments	(7)
Ending balance	34
Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	42
Cumulative Effect of Accounting Change	(28)	[1]
Payments	(4)
Ending balance	10
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	4	[3]
Costs incurred	3	[3]
Payments	(3)	[3]
Ending balance	$ 4	[3]
[1]	Impact of adopting new lease accounting guidance on January 1, 2019.
[2]	Represents reductions in cost of plans.
[3]	Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.